Table 2. Comorbidities of the patients included in the study.

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; AZI-M/CT, azilsartan-medoxomil/chlorthalidone; OLM/HCTZ, olmesartan-medoxomil/hydrochlorothiazide; n, number of patients; SD, standard deviation; N/A, not available

Study and year	Diabetes, n  (%)		CKD , n  (%)		Mean SBP (SD)		Mean DBP (SD)		Mean BMI (SD)
	AZI-M/CT	OLM/HCTZ	AZI-M/CT	OLM/HCTZ	AZI-M/CT	OLM/HCTZ	AZI-M/CT	OLM/HCTZ	AZI-M/CT	OLM/HCTZ
Cushmann et al. (2012) [5]	113 (32)	65 (17.9)	N/A	N/A	150 (13.7)	149 (14)	88.25 (10.9)	87.1 (11)	31.65 (6.27)	31.6 (5.92)
Neutel et al. (2017) [11]	62 (15)	59 (14)	58 (14)	50 (12)	168 (7)	167.6 (7)	95.7 (9.2)	95.7 (9.6)	31.4 (6.2)	31.9 (6.6)
Cushmann et al. (2018) [12]	117 (16)	71 (19.9)	66 (9.1)	66 (9.1)	165 (10.6)	164.7 (10.4)	95.3 (10.25)	96.1 (10.4)	31.7 (6.1)	31.9 (6.1)
Bakris et al. (2018) [13]	33 (42.9)	32 (42.1)	N/A	N/A	151.1 (10.3)	149 (7.8)	84.8 (10.31)	84.7 (9.68)	30.4 (6.23)	31.6 (6.52)